Baxter International Inc. logo
Baxter International Inc. (BAX)
Compare

BAX Balance Sheet

Assets, liabilities, and equity analysis

BAX Quarterly Balance Sheet (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Total Current Assets
6.847B6.847B6.872B6.933B6.749B7.035B8.853B8.864B8.593B
2.017B2.017B1.966B1.726B1.686B2.294B1.764B1.420B2.095B
Short-Term Investments
0.000.000.000.000.000.000.000.000.00
Cash & Short-Term Investments
2.017B2.017B1.966B1.726B1.686B2.294B1.764B1.420B2.095B
1.698B1.698B1.932B1.777B1.773B1.646B1.730B1.729B2.639B
2.316B2.316B2.232B2.460B2.384B2.170B2.046B2.103B2.985B
Total Assets
19.846B19.846B20.055B21.067B21.046B21.304B25.782B26.676B26.312B
3.190B3.190B3.186B3.082B3.091B3.018B3.176B3.160B4.838B
4.899B4.899B4.929B5.400B5.395B5.338B5.275B5.783B6.001B
Intangible Assets
4.218B4.218B4.369B4.805B4.950B5.081B5.223B5.449B5.741B
Long-Term Investments
113.000M113.000M103.000M126.000M114.000M117.000M109.000M126.000M168.000M
Total Current Liabilities
3.693B3.693B2.970B3.775B2.939B3.481B6.511B6.200B6.131B
1.086B1.086B999.000M953.000M995.000M963.000M968.000M841.000M1.251B
842.000M842.000M1.000M755.000M8.000M662.000M2.752B2.498B2.468B
Total Liabilities
13.830B13.830B13.953B13.853B13.753B14.250B18.758B18.734B18.604B
8.621B8.621B9.473B8.747B9.492B9.412B10.374B10.437B10.436B
9.687B9.687B9.780B9.712B9.725B10.309B13.449B13.194B13.343B
Net Debt (Cash)
7.670B7.670B7.814B7.986B8.039B8.015B11.685B11.774B11.248B
Total Shareholders' Equity
6.043B6.043B6.129B7.241B7.320B7.081B6.964B7.872B7.643B
Common Stock
683.000M683.000M683.000M683.000M683.000M683.000M683.000M683.000M683.000M
13.685B13.685B13.705B14.837B14.970B14.968B14.929B15.529B15.539B
1.851.852.311.842.302.021.361.431.40
1.601.601.601.341.331.461.931.681.75

BAX Annual Balance Sheet (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Current Assets
6.872B8.853B9.600B8.011B8.872B8.411B7.503B5.959B
1.966B1.764B3.078B1.718B2.951B3.730B3.335B1.838B
Short-Term Investments
0.000.000.000.000.000.000.000.00
Cash & Short-Term Investments
1.966B1.764B3.078B1.718B2.951B3.730B3.335B1.838B
1.932B1.730B1.772B2.623B2.713B2.077B1.896B1.840B
2.232B2.046B1.918B2.679B2.453B1.916B1.653B1.667B
Total Assets
20.055B25.782B28.276B28.287B33.521B20.019B18.193B15.720B
3.186B3.176B3.207B5.236B5.808B5.325B5.120B4.530B
4.929B5.275B5.793B6.452B9.836B3.217B3.030B3.002B
Intangible Assets
4.369B5.223B5.918B6.793B7.792B1.671B1.471B1.410B
Long-Term Investments
103.000M109.000M136.000M247.000M195.000M135.000M76.000M44.000M
Total Current Liabilities
2.970B6.511B6.503B4.745B4.236B3.333B3.230B2.814B
999.000M968.000M881.000M1.110B1.246B1.043B892.000M998.000M
84.000M2.752B2.667B1.404B511.000M406.000M541.000M4.000M
Total Liabilities
13.953B18.758B19.808B22.392B24.400B11.293B10.281B7.854B
9.675B10.374B11.089B15.232B17.149B5.786B4.809B3.481B
10.003B13.449B14.113B17.203B18.310B6.804B5.961B3.485B
Net Debt (Cash)
8.037B11.685B11.035B15.485B15.359B3.074B2.626B1.647B
Total Shareholders' Equity
6.129B6.964B8.402B5.833B9.077B8.689B7.882B7.844B
Common Stock
683.000M683.000M683.000M683.000M683.000M683.000M683.000M683.000M
13.705B14.929B16.114B14.050B17.065B16.328B15.718B15.075B
2.311.361.481.692.092.522.322.12
1.631.931.682.952.020.780.760.44

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Baxter International Inc.

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Deerfield, IL
38,000 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Andrew Hider